Related Experiment Video

Updated: May 3, 2026

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure
10:07

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure

Published on: March 20, 2012

27.2K

Gene expression in teratogenic exposures: a new approach to understanding individual risk

Claudia Kappen1, J Michael Salbaum2

  • 1Department of Developmental Biology, Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, LA 70808, United States.

Reproductive Toxicology (Elmsford, N.Y.)
|February 5, 2014
PubMed

Insights

Many teratogen exposures cause incomplete penetrance, where not all exposed individuals develop defects. Focusing on variations between exposed individuals can reveal susceptibility factors for developmental abnormalities.

Area of Science:

  • Reproductive toxicology
  • Developmental biology
  • Genetics

Background:

  • Partial or incomplete penetrance is a common phenomenon in teratogen exposure studies.
  • Existing experimental approaches in reproductive toxicology often overlook this variability.
  • This oversight may lead to missed differences contributing to teratogenesis susceptibility.

Purpose of the Study:

  • To highlight the limitations of current experimental designs in reproductive toxicology regarding incomplete penetrance.
  • To propose a shift in research focus towards inter-individual variation in teratogen exposure studies.
  • To identify factors contributing to susceptibility in developmental defects with incomplete penetrance.

Main Methods:

  • Review of current experimental methodologies in reproductive toxicology.
  • Conceptual analysis of partial penetrance in teratogenesis.
  • Proposal for a variation-focused research approach.

Main Results:

  • Standard experimental approaches may fail to detect critical differences between affected and unaffected individuals.
  • Variation among exposed individuals is a crucial, yet underutilized, data source.
  • Identifying these variations can uncover causative factors for incomplete penetrance teratogenesis.

Conclusions:

  • Current reproductive toxicology methods are insufficient for fully understanding incomplete penetrance.
  • Investigating inter-individual variability is essential for advancing the study of teratogenesis.
  • This approach promises to uncover novel insights into developmental defect susceptibility.
Keywords:
Gene expressionMaternal diabetesMouse modelNeural tube defectPhenotypeSusceptibilityTeratogen exposureVariation

More Related Videos

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

666
Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

1.6K

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Gene-Environment Interactions01:20

Gene-Environment Interactions

Gene expression is a dynamic process that is significantly influenced by environmental factors. This interaction underlies the complex nature of biological development and the phenotypic differences observed among individuals, even among those with identical genetic makeups. Factors such as radiation, temperature, behavior, nutrition, and stress play pivotal roles in determining how genes are expressed. The concept of the reaction range is central to understanding this interaction. It posits...
1.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K